Metsera, Inc. (NASDAQ:MTSR - Get Free Report) shares shot up 4.7% during trading on Monday . The stock traded as high as $20.71 and last traded at $20.49. 137,510 shares traded hands during trading, a decline of 83% from the average session volume of 830,136 shares. The stock had previously closed at $19.57.
Analyst Ratings Changes
A number of brokerages have weighed in on MTSR. Bank of America started coverage on Metsera in a report on Tuesday, February 25th. They issued a "buy" rating and a $38.00 price objective on the stock. Cantor Fitzgerald initiated coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued an "overweight" rating on the stock. Guggenheim initiated coverage on shares of Metsera in a research note on Tuesday, February 25th. They set a "buy" rating and a $56.00 price objective for the company. Finally, Evercore ISI began coverage on shares of Metsera in a report on Tuesday, February 25th. They issued an "outperform" rating for the company.
Get Our Latest Stock Report on MTSR
Metsera Price Performance
The firm has a fifty day simple moving average of $24.08.
Metsera (NASDAQ:MTSR - Get Free Report) last posted its earnings results on Wednesday, March 26th. The company reported ($3.52) earnings per share for the quarter.
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Recommended Stories
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
